Trial Profile

A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (Aged 2 to 11 Years) With Moderate-to-Severe Atopic Dermatitis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 31 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Jul 2026 According to a Galderma media release, submission preparation ongoing of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis in the U.S., following clinically meaningful late-breaking data presented in the first quarter.
28 Mar 2026 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting, according to Galderma Media Release.
28 Mar 2026 Results presented in the Galderma Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com